Postoperative Hypofractionated Radiation in Cervical and Endometrial Tumours: Phase II Study

Cervical Cancer Clinical Trial

— PARCERII  

Official title:

Postoperative Hypofractionated Radiation in Cervical and Endometrial Tumours: Phase II Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05857631
• Other study ID #: 3910
• Secondary ID: CTRI/2023/02/050
• Status: Recruiting
• Phase: N/A
• Start date: May 29, 2023
• Est. completion date: May 25, 2029

Study information

• Verified date: November 2023
• Source: Tata Memorial Centre
• Contact: Dr. Prachi D Mittal, MD
• Phone: +91 9004938871
• Email: mittalprachi[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary aim of the trial is to investigate the late effects of hypofractionated external radiation (39 Gy in 13 fractions) in patients requiring post-operative radiation for early-stage cervical and endometrial cancers.

Description:

This is a phase II prospective study that will be accruing patients with post operative cervical or endometrial cancer requiring adjuvant pelvic radiation.

External beam radiotherapy (Intensity modulated radiotherapy/arc technique) will be delivered to pelvis to a dose of 39 Gray (Gy) in 13 fractions at 3 Gy per fraction, delivered once daily over 2.5 - 3 weeks. Treatment will be delivered with Intensity Modulated Radiotherapy (IMRT) under image guidance. Patients for whom concurrent chemotherapy is indicated (as per adverse risk features) will receive concurrent weekly cisplatin (40mg/m2) based on standard institutional protocol. All patients with post-operative cervical cancer will receive vaginal brachytherapy after the completion of external beam radiation. Patients with endometrial cancer with certain pre defined risk factors will also receive vaginal brachytherapy. The dose of vaginal brachytherapy will be 6 Gy high dose rate brachytherapy delivered as two different fractions, one week apart. Patients will be evaluated by the concerned investigators on a weekly basis during radiation therapy and all the toxicities will be documented according to the CTCAE V 5.0.

Patients will be followed up 3 monthly for the first 2 years, then 6 monthly from years 2 - 5, and annually thereafter. CTCAE version 5 will be used for toxicity grading at each follow-up. Quality of life assessment will be performed at baseline prior to the start of radiation and on follow-up at pre-specified times using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-C30) and Cervix - 24 (CX24) for cervical cancer patients and Endometrium 24 (EN24) for endometrial cancer patients.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 90
• Est. completion date: May 25, 2029
• Est. primary completion date: May 25, 2026
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2

2. Histologically confirmed diagnosis of cervical cancer post hysterectomy with intermediate or high-risk features, requiring adjuvant EBRT ± concurrent chemotherapy OR histologically confirmed diagnosis of endometrial cancer post hysterectomy requiring adjuvant (chemo)radiotherapy to pelvis with/without vaginal brachytherapy.

Exclusion Criteria:

1. Patients with macroscopic residual disease (R+ resection) postoperatively

2. Patients requiring extended field radiotherapy (patients with involved para-aortic lymph nodes in cervical or endometrial cancer)

3. Patients treated with chemotherapy for any prior malignancy at any time

4. Patients treated with pelvic radiation previously

5. Patients with human immunodeficiency virus infection

6. Any preexisting medical conditions that may interfere with the assessment of genitourinary or gastrointestinal toxicity (This includes patients with irritable bowel syndrome, subacute intestinal obstruction, anal incontinence, hemorrhoids precluding analysis of gastro-intestinal toxicities, urinary incontinence, recurrent urinary tract infections)

Related Conditions & MeSH terms

• Cervical Cancer
• Endometrial Cancer
• Endometrial Neoplasms

Intervention

Radiation:
• Hypofractionated Image guided External Beam Radiation Therapy (EBRT)
External beam radiotherapy to pelvis: Post operative hypofractionated external beam radiotherapy with intensity modulated/arc technique, to a dose of 39 Gy in 13 fractions, at 3 Gy per fraction, delivered once daily, 5 days a week, over 2.5-3 weeks.

Drug:
• Cisplatin
Patients who require adjuvant chemotherapy along with radiation, based on predefined risk features, will receive 5 cycles of cisplatin on a weekly basis with a dose of 40 mg/m2 by IV infusion over a period of 1 hour 2-4 hours prior to start of EBRT.

Radiation:
• Vaginal brachytherapy
Vaginal brachytherapy, two fractions of 6 Gy each, delivered 1 week apart.

Locations

Country	Name	City	State
India	Tata Memorial Hospital	Mumbai	Maharashtra
India	Advanced Centre for Treatment Research and Education in Cancer (ACTREC)	Navi Mumbai	Maharahstra

Sponsors (1)

Lead Sponsor	Collaborator
Tata Memorial Centre

Country where clinical trial is conducted

India, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	3-year cumulative incidence of grade =2 gastrointestinal or genitourinary toxicity	To evaluate the 3-year cumulative incidence of late grade =2 gastrointestinal or genitourinary toxicity using CTCAE version 5 scoring receiving radiation with hypo fractionation.	Median follow up of 3 years
Secondary	Pelvic Control Rate at 3 years	To report 3 year pelvic control rate (local and pelvic nodal) in patients receiving hypofractionated radiotherapy.	Median follow up of 3 years
Secondary	Disease Free Survival at 3 years	To report 3 year disease free survival in patients receiving hypo fractionated radiotherapy.	Median follow up of 3 years
Secondary	Overall Survival at 3 years	To report 3 year overall survival in patients receiving hypo fractionated radiotherapy.	Median follow up of 3 years
Secondary	Acute Toxicities Evaluation	Acute toxicity will be reported using CTCAE V. 5.0	3 months
Secondary	Assessment of Quality of Life for cervical cancer patients	To assess quality of life in using EORTC QLQ-C30 and CX24. Quality of life will be measured using the EORTC QLQ C-30. For cervical cancer, EORTC QLQ CX24 module will be used. QOL scoring will be done as per standard recommendations outlined in EORTC QLQ C30 scoring manual. All patients will undergo QOL evaluation at baseline, after treatment and at subsequent follow-up.Scale- Not at all-1 , A little Bit-2, Quite a bit-3, very much-4.; 1 will be considered as better outcome & 4 will be considered as worst outcome.	Median follow up of 3 years
Secondary	Assessment of Quality of Life for endometrial cancer patients	To assess quality of life in using EORTC QLQ-C30 and EN24. Quality of life will be measured using the EORTC QLQ C-30. For endometrial tumours, EORTC QLQ EN24 will be used. QOL scoring will be done as per standard recommendations outlined in EORTC QLQ C30 scoring manual. All patients will undergo QOL evaluation at baseline, after treatment and at subsequent follow-up.Scale- Not at all-1 , A little Bit-2, Quite a bit-3, very much-4.; 1 will be considered as better outcome & 4 will be considered as worst outcome.	Median follow up of 3 years
Secondary	C-MOSES scoring	To report cumulative toxicity score as assessed by C-MOSES scoring. Month and Severity Score (MOSES) will be calculated for each symptom (13 gastrointestinal and 6 genitourinary) with time weighted CTCAE toxicity, by using duration of time spent in each toxicity. Cumulative-MOSES score will be assessed for organ system (gastrointestinal and genitourinary), by summating MOSES of individual adverse event items respectively.	Median follow up of 3 years